Melbourne, June 26, 2026, 02:05 (AEST)
- CSL finished the session up 2.3% at A$117.65. The S&P/ASX 200 dropped 0.68%.
- The stock has bounced 27.6% since its June 3 closing low, regaining about A$12.2 billion in equity value.
- CSL Limited reports full-year results and its final dividend on August 18.
CSL Limited ASX:CSL climbed A$2.66 to A$117.65 on Thursday. The stock is up 5.0% over two sessions. Healthcare names rose 2.6%, while the broader Australian market traded lower.
ASX moves on Tuesday had the feel of a currency and sector play, not a reaction to CSL earnings. The Aussie dollar fell to 68.91 US cents, lifting the local dollar value of earnings made in US dollars. IG analyst Tony Sycamore said a “renewed slide in key commodity prices” was the driver as the US dollar got stronger. IG
CSL hasn’t released a new operating update. The company’s most recent filing is a June 9 securities cessation notice, and before that the May 11 operating review from interim CEO Gordon Naylor.
The stock is up from its A$92.24 close on June 3. That’s a jump of A$25.41, lifting market value by roughly A$12.2 billion with 478.91 million shares out.
At Thursday’s exchange rate, the extra US$5 billion non-cash, pre-tax write-down flagged back in May comes out to about A$7.3 billion. Shares have since clawed back market value since June 3, gaining about 1.7 times that loss. The rally now goes further than just erasing the write-down hit; the market is also pricing in some better execution, even though guidance hasn’t changed.
CSL has an equity value near A$56.3 billion. Using spot exchange rates, the company’s US$3.1 billion NPATA forecast for FY26 values the stock at about 12.5 times its guided underlying profit. That number leaves out any restructuring and impairment charges. “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise,” Naylor said. Morningstar, Inc.
CSL is guiding to FY26 revenue near US$15.2 billion. The company said normalising US immunoglobulin channel inventory should knock off around US$300 million in revenue. Lower value in China’s albumin market is set to reduce revenue by US$200 million, with further pressures adding another US$150 million in cuts.
Morningstar equity strategist Lochlan Halloway wrote this month, “Shares are undervalued as we are likely more optimistic than the market on plasma demand and margins.” Halloway said the next thing to watch is a clear drop in plasma collection costs. He added that price competition could eat into some of CSL’s cost savings. Morningstar
Broker ratings are still spread out. UBS kept its buy and A$158 target. Ord Minnett stayed at hold with a A$117 target. Out of seven brokers tracked by Market Index, five rate the stock a hold, with the average target price at A$137.04.
CSL saw 1.95 million shares change hands Thursday, matching its usual daily pace. That’s still much lower than the 8.16 million shares traded when the stock shot up 7.6% on June 19. Even after the bounce, shares are off 32.2% in 2026.
CSL will report its full-year results and announce the final dividend on August 18.
Related articles: ASX:CSL
